SCHEMBL4305953

SCHEMBL4305953

COC(=O)c1cccc(C(=O)N2CCC(NC(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4D Q6B0I6 2/20 0.54
▸ EPHX2 P34913 1/20 0.53
▸ PARP1 P09874 2/20 0.52
▸ RBP4 P02753 1/20 0.51
▸ CFTR P13569 1/20 0.50
▸ NAMPT P43490 1/20 0.50
▸ RHOA P61586 1/20 0.48
▸ USP30 Q70CQ3 2/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ HSD11B1 P28845 1/20 0.47
▸ CACNA1B Q00975 1/20 0.46
▸ CTSK P43235 2/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13631107 0.90 PARP1 (0.53) EPHX2PARP1CFTRNAMPTUSP30
SCHEMBL7718973 0.88 PARP1 (0.53) KDM4DPARP1CFTRNAMPTUSP30
SCHEMBL7718971 0.88 PARP1 (0.53) KDM4DPARP1CFTRNAMPTUSP30
SCHEMBL4292513 0.87 PARP1 (0.49) KDM4DEPHX2PARP1CFTRNAMPT
SCHEMBL2610266 0.86 NAMPT (0.61) PARP1NAMPTUSP30HDAC3HDAC1
SCHEMBL7939466 0.86 NAMPT (0.61) PARP1NAMPTUSP30HDAC3HDAC1
SCHEMBL3764862 0.85 PARP1 (0.51) KDM4DPARP1CFTRNAMPTUSP30
SCHEMBL16161673 0.85 PARP1 (0.51) KDM4DPARP1CFTRNAMPTUSP30
SCHEMBL16771646 0.84 PARP1 (0.52) KDM4DPARP1CFTRNAMPTUSP30
SCHEMBL4297696 0.83 PADI4 (0.47) KDM4DEPHX2PARP1CFTRNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO claimed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 KDM4D 4487/4885EPHX2 3299/4885PARP1 3598/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 KDM4D 4609/4885EPHX2 2785/4885PARP1 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback